skip to content »


Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Journal Publications by MSCCC Members

Click on the Expand plus sign sign to list the journal publications by year. Then click on the PubMed link for details of that publication.

Time Line

Expand All


Collapse All | Expand All


  • Rivera VM, Medina MT, Duron RM, Macias MA. Multiple sclerosis care in Latin America. Neurology. 2014;82(18):1660-1. [view publication]


Collapse All | Expand All


  • Macias-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013;113(4):415-20. [view publication]
  • Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013;13(1):80. [view publication]


Collapse All | Expand All


  • Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. IFN-beta induces the proliferation of CD4(+)CD25(+)Foxp3(+) regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012;242(1-2):39-46. [view publication]


Collapse All | Expand All


  • Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther. 2011;11(7):961-7. [view publication]
  • Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77(5):505-7. [view publication]
  • Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4(1):3-14. [view publication]
  • Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010;26(4):827-38. [view publication]
  • Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010;4:219. [view publication]
  • Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):751-7. [view publication]
  • Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2010;74(10):864. [view publication]
  • Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-541. [view publication]
  • Hutton GJ, Avila M, Suarez GA. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009;111(3):309-10. [view publication]
  • Rivera VM. Multiple Sclerosis in Latin America. Reality and Challenge. Neuroepidemiology. 2009;32(4):294-295. [view publication]
  • Brodsky M, Orengo-Nania S, Hutton GJ, Slight B, Buckley EG, Massey EW, et al. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082 e5. [view publication]
  • Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008;14(3):370-82. [view publication]
  • Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801. [view publication]
  • Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039-47. [view publication]
  • Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, et al. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain. 2008;131(Pt 2):e89; author reply e90. [view publication]
  • Suarez Zambrano GA, Hutton GJ. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008;65(10):1388-9. [view publication]
  • Cristiano E, Arcega R, Correale J, Gabbay AA, Lander-Delgado R, Macias-Islas MA, et al. [Recommendations for optimising the treatment of multiple sclerosis in Latin America]. Rev Neurol. 2007;44(8):494-8. [view publication]
  • Ordonez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin Neurol Neurosurg. 2007;109(1):102-5. [view publication]
  • Rivera-Olmos VM, Avila MC. [Multiple sclerosis in Latin America. Are McDonald's criteria really applicable?]. Rev Mex Neuroci. 2007;8(1):49-56. [view publication]
  • Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):705-9. [view publication]
  • Carra A, Rivera-Olmos V, Arcega R, Gabbai A, Haussen SR, Luetic G, et al. [The treatment of multiple sclerosis in Latin America: current practice and optimal standards. The findings of a survey among neurologists at an interactive workshop]. Rev Neurol. 2006;42(7):399-407. [view publication]
  • Harris AM, Thompson B, Chamberlain J, Dawson M, Perry I, Rechtin E, et al. Satisfaction with life during the first two years of medical school based on sleep, diet, and exercise and current adherence to future patient advice. J Int Assoc Med Sci Educ. 2006;16(2):86-92. [view publication]
  • Skromne E, Rivera VM, Ontaneda D, Ordonez L. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology. 2006;66(11):1787-8; author reply 1787-8. [view publication]
  • Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2005;64(12):2163. [view publication]
  • Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 2005;19(9):725-7. [view publication]
  • Rivera VM. The terms Latino and Anglo and tendency to early Alzheimer disease. Arch Neurol. 2005;62(11):1787; author reply 1787-8. [view publication]
  • Rivera-Olmos VM, Lozano JA. [Cogan's syndrome: Neurological manifestations. Case report and review of literature]. Rev Mex Neuroci. 2005;6(1):97-101. [view publication]
  • Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005;56:273-302. [view publication]
  • Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S3-11. [view publication]
  • Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-39. [view publication]
  • Hong J, Zang YC, Li S, Rivera VM, Zhang JZ. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol. 2004;34(3):870-81. [view publication]
  • Rivera VM. Esclerosis multiple: evidencias, genericos y similares. Rev Mex Neuroci. 2004;5(4):286-7.
  • Rivera-Olmos VM, Hutton GJ, Breitbach WT. Discrepancia entre clinica e imagen: esclerosis multiple en fase intermedia. Presentacion de un caso y revision del tema [Discrepancy between clinics and image techniques: intermediate phase of multiple sclerosis. A case report and review of the literature]. Rev Mex Neuroci. 2004;5(2):158-62. [view publication]
  • Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. [view publication]
  • Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004;172(8):5120-7. [view publication]
  • Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10(5):499-506. [view publication]
  • Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61(5):602-11. [view publication]
  • Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Jr, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003;61(6):848-50. [view publication]
  • Rivera VM. [Deciding on treatment in multiple sclerosis]. Rev Neurol. 2003;36(1):80-5. [view publication]
  • Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003;53(2):189-97. [view publication]
  • Velazquez-Quintana M, Macias-Islas MA, Rivera-Olmos V, Lozano-Zarate J. [Multiple sclerosis in Mexico: a multicentre study]. Rev Neurol. 2003;36(11):1019-22. [view publication]
  • Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003;137(1-2):144-53. [view publication]
  • Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003;15(9):1073-80. [view publication]
  • Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002;8(3):237-42. [view publication]
  • Rivera VM. II Congreso de LACTRIMS. Rev Neurol. 2002;35(12):1175-6.
  • Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunology. 2002;107(4):403-10. [view publication]
  • Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002;76(12):6147-54. [view publication]
  • Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol. 2002;124(1-2):106-14. [view publication]
  • Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002;24(12):1998-2021. [view publication]
  • Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002;249(2):212-8. [view publication]
  • Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology. 2001;57(2):239-45. [view publication]
  • Rivera VM, Cabrera JA. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001;57(5):937-8. [view publication]
  • Rivera VM. [Neuroimaging in multiple sclerosis]. Rev Neurol. 2001;32(3):283-5. [view publication]
  • Rivera VM. [Pharmacologic treatment of multiple sclerosis]. Rev Neurol. 2001;32(3):285-8. [view publication]
  • Rivera VM. La decada del cerebro. Neurociencia. 2001;2(13):131.
  • Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001;31(3):907-17. [view publication]
  • Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001;112(1-2):174-80. [view publication]
  • Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000;165(12):6858-64. [view publication]
  • Rivera VM, Cabrera JA. La Esclerosis Multiple en Latino America. MEDICO Interamericano. 2000;19(10):458-65.
  • Rivera VM. [The treatment of multiple sclerosis with beta-interferon 1a]. Rev Neurol. 2000;31(5):470-1. [view publication]
  • Rivera VM. Grupo de Estudio de EM (Mexico): Uso de Agentes Modificadores de la Enfermedad. Neurociencia. 2000;3:29-30.
  • Rivera VM. Introduccion al Simposio Latino Americano. Rev Neurol. 2000;31(5):469.
  • Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000;12(12):1641-50. [view publication]
  • Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000;164(8):4011-7. [view publication]
  • Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000;30(3):908-13. [view publication]
  • Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000;123 ( Pt 9):1874-82. [view publication]
  • Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000;55(3):397-404. [view publication]
  • Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, et al. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol. 1999;163(6):3530-8. [view publication]
  • Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999;98(2):201-7. [view publication]
  • Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53(8):1692-7. [view publication]
  • Singh RA, Zang YC, Shrivastava A, Hong J, Wang GT, Li S, et al. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J Immunol. 1999;163(12):6393-402. [view publication]
  • Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999;29(5):1692-700. [view publication]
  • Kozovska M, Zang YC, Aebischer I, Lnu S, Rivera VM, Crowe PD, et al. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur J Immunol. 1998;28(6):1894-901. [view publication]
  • Zang YC, Kozovska M, Aebischer I, Li S, Boehme S, Crowe P, et al. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. Int Immunol. 1998;10(7):991-8. [view publication]
  • Jerger J, Alford B, Lew H, Rivera V, Chmiel R. Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. Ear Hear. 1995;16(5):482-98. [view publication]
  • Trujillo JR, Garcia-Ramos G, Novak IS, Rivera VM, Huerta E, Essex M. Neurologic manifestations of AIDS: a comparative study of two populations from Mexico and the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(1):23-9. [view publication]
  • Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, et al. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994;20(3):434-44; discussion 442-3. [view publication]
  • Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, et al. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991;13(1):36-45; discussion 45-6. [view publication]
  • Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJR Am J Roentgenol. 1990;155(6):1303-7. [view publication]
  • Rivera VM. Safety of intrathecal steroids in multiple sclerosis. Arch Neurol. 1989;46(7):718-9. [view publication]
  • Jerger JF, Oliver TA, Chmiel RA, Rivera VM. Patterns of auditory abnormality in multiple sclerosis. Audiology. 1986;25(4-5):193-209. [view publication]
  • Rivera VM. Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986;79(8):217-32. [view publication]
  • Hannley M, Jerger JF, Rivera VM. Relationships among auditory brain stem responses, masking level differences and the acoustic reflex in multiple sclerosis. Audiology. 1983;22(1):20-33. [view publication]
  • Rivera VM. Intraspinal steroid therapy. Neurology. 1981;31(8):1060-1. [view publication]
  • Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. Arch Neurol. 1980;37(4):201-3. [view publication]
  • Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979;6(3):227-31. [view publication]
  • Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: a new syndrome. Trans Am Neurol Assoc. 1978;103:116-8. [view publication]
  • Perez FI, Hruska NA, Stell RL, Rivera VM. Computerized assessment of memory performance in dementia. Can J Neurol Sci. 1978;5(3):307-12. [view publication]
  • Rivera VM, Patten BM. Neuromyopathy in malignant hyperthermia. J Clin Psychiatry. 1978;39(1):67-71. [view publication]
  • Rivera VM. Acute hypokalemic myopathy in alcoholism. Arch Neurol. 1978;35(9):619. [view publication]
  • Guido EM, Rivera VM. Precordialgia as a manifestation of vertebrobasilar insufficiency. J Am Geriatr Soc. 1977;25(10):463-5. [view publication]
  • Rivera VM. Viruses and multiple sclerosis. Jama. 1977;238(12):1247. [view publication]
  • Rodriguez J, Rivera VM. Risk factors in stroke in a Mexican-American population (Houston). Neurol Neurocir Psiquiatr. 1977;18(2-3 Suppl):225-34. [view publication]
  • Perez FI, Gay JR, Taylor RL, Rivera VM. Patterns of memory performance in the neurologically impaired aged. Can J Neurol Sci. 1975;2(4):347-55. [view publication]
  • Perez FI, Rivera VM, Meyer JS, Gay JR, Taylor RL, Mathew NT. Analysis of intellectual and cognitive performance in patients with multi-infarct dementia, vertebrobasilar insufficiency with dementia, and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1975;38(6):533-40. [view publication]
  • Rivera VM, Breitbach WB, Swanke L. Letter: dantrolene in amyotrophic lateral sclerosis. Jama. 1975;233(8):863-4. [view publication]
  • Rivera VM, Keichian AH, Oliver RE. Persistent parkinsonism following neuroleptanalgesia. Anesthesiology. 1975;42(5):635-7. [view publication]

E-mail this page to a friend